Wedbush Maintains Outperform on CytomX Therapeutics, Raises Price Target to $12
Benzinga Newsdesk 34 minutes ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and raises the price target from $11 to $12.
Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and raises the price target from $11 to $12.